NVG-2089 / Nuvig Therapeutics - LARVOL DELTA

INVGOR: Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Nuvig Therapeutics, Inc.

New P2 trial • Pain

A PHASE 1 HEALTHY VOLUNTEER DOSE ESCALATION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS (PK), AND PHARMACODYNAMICS (PD) OF INTRAVENOUS HUMAN IGG1 FC-F241A (NVG-2089) FOR THE TREATMENT OF ITP (EHA 2025) - "NVG-2089 was well tolerated in healthy subjects with exposures that will enable dosing intervals of 2-4 weeks to achieve modeled efficacious exposures. PD responses following treatment with NVG-2089 were consistent with that observed in humans following treatment with 1-2g/kg IVIg. These data support further development of NVG-2089 in patients with ITP and other autoimmune diseases."

Clinical • P1 data • PK/PD data • Immunology • ENTPD1 • FCER2